BioCentury | Mar 19, 2021
Product Development

Self-amplifying may be the next frontier in RNA therapies

With the success of mRNA vaccines for COVID-19 solidifying the technology as a vaccine modality that’s here to stay, the conversation has turned to where mRNA will make its mark next and what’s...
BioCentury | Dec 18, 2020
Product Development

Sangamo’s Macrae on where the gene editing field is headed: a BioCentury audio interview

Gene-editing assets may be the next additions to big pharma shopping lists as gene therapies are now becoming core modalities alongside small molecules and mAbs, according to Sandy Macrae, who anticipates...
BioCentury | Dec 8, 2020
Product Development

ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal

...with Seattle Genetics Inc. focused on ADCs against LIV-1...
...Epidermal growth factor receptor 2 LIV-1 (SLC39A6; ZIP6...
BioCentury | Sep 15, 2020

With $1.7B in Merck deals, Seattle Genetics plots broader pipeline

...LIV-1. The antibody-drug conjugate (ADC) comprises a LIV-1...
...Epidermal growth factor receptor 2LIV-1 (SLC39A6; ZIP6...
...calcium signal transducer 2 Virginia Li ladiratuzumab vedotin (SGN-LIV1A, anti-liv-1...
BioCentury | Sep 15, 2020
Product Development

Data Bytes: Trodelvy leads TROP2 pack

Five therapies in the TROP2 pipeline together address at least seven types of cancer plus undisclosed solid tumors. The most advanced, Trodelvy sacituzumab govitecan-hziy, is the centerpiece of the $21 billion acquisition of Immunomedics Inc. by...
BioCentury | Sep 9, 2020
Product Development

BMS’s Hirawat says health equity should be on all biopharmas’ agendas: a BioCentury audio interview

BMS CMO Samit Hirawat believes that all biopharmas can, and should, contribute to eliminating racial, ethnic and socioeconomic disparities in health outcomes. The responsibility, he says, extends from working with minority communities directly to holding...
BioCentury | Aug 27, 2020
Product Development

Freenome maps path forward for blood-based cancer screenings with $270M C round

Freenome’s $270 million series C will fuel the company’s push to move its multiomics cancer screening technology beyond colorectal cancer. New investor Bain Capital Life Sciences and existing investor...
BioCentury | May 8, 2020

Follow-on market poised for comeback, at least temporarily

Pandemic-driven market volatility has stymied follow-on activity the past two months, but stabilizing markets and big inflows are opening a window of opportunity, at least in the near term. The unfolding consequences of COVID-19 could...
BioCentury | Sep 13, 2018
Emerging Company Profile

Mapping tumor markers

BioGraph 55 Inc. is mapping immune cells in the tumor microenvironment to identify cell-to-cell interaction patterns that can help match patients to existing therapies and identify novel therapeutic targets. The newco is developing a pipeline...
BioCentury | Aug 9, 2018
Preclinical News

New biological insight could lead to obesity treatment

By identifying a mechanism in dietary fat uptake, researchers from Yale University School of Medicine suggest a compound marketed for glaucoma could have therapeutic applications in obesity. The study was published Thursday in Science. Dietary...
Items per page:
1 - 10 of 83